A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/17/2002	WO2002081709A2 Modified hpv e6 and e7 genes and proteins useful for vaccination
10/17/2002	WO2002081705A2 Regulation of human gnat acetyltransferase-like protein
10/17/2002	WO2002081703A2 Mitogenic oxygenase regulators
10/17/2002	WO2002081668A2 Desaturase genes and uses thereof
10/17/2002	WO2002081661A2 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
10/17/2002	WO2002081649A2 ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
10/17/2002	WO2002081646A2 Epitope sequences
10/17/2002	WO2002081636A2 Protein modification and maintenance molecules
10/17/2002	WO2002081627A2 Methods of screening and using inhibitors of angiogenesis
10/17/2002	WO2002081520A2 Single chain dimeric polypeptides derived from the vegf family
10/17/2002	WO2002081508A2 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	WO2002081506A1 Process for producing trunkamide a compounds
10/17/2002	WO2002081499A2 Somatostatin agonists
10/17/2002	WO2002081496A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
10/17/2002	WO2002081494A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	WO2002081491A2 New genistein derivatives and pharmaceutical preparations containing them
10/17/2002	WO2002081484A1 Tumour inhibiting gallium compounds
10/17/2002	WO2002081482A1 Compounds and methods for inhibiting mrp1
10/17/2002	WO2002081481A1 Compounds and methods for inhibiting mrp1
10/17/2002	WO2002081480A1 Compounds and pharmaceutical compositions for inhibiting mrp1
10/17/2002	WO2002081478A2 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081471A1 Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
10/17/2002	WO2002081467A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
10/17/2002	WO2002081466A1 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
10/17/2002	WO2002081462A1 Aminoflavone compounds, compositions, and methods of use thereof
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081445A1 Indolinones, substituted in position 6, and their use as kinase inhibitors
10/17/2002	WO2002081415A2 Method for inhibiting metap2
10/17/2002	WO2002080987A1 Anti-cd19 immunotoxins
10/17/2002	WO2002080981A2 Polynucleotide binding complexes comprising sterols and saponins
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080976A2 Hsa-free formulations of interferon-beta
10/17/2002	WO2002080975A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
10/17/2002	WO2002080972A1 Association of a tumor antigen and a system for delivering a cytokine or a chemokine for cancer immunotherapy purposes
10/17/2002	WO2002080966A2 Method for producing a vaccine containing autologous antibodies
10/17/2002	WO2002080958A1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
10/17/2002	WO2002080955A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080947A1 Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same
10/17/2002	WO2002080940A2 Pharmacologically active strong acid solutions
10/17/2002	WO2002080937A1 Antineoplastic compositions comprising trk tyrosine kinase inhibitors and nucleotide analogs
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080923A1 Substances for use in therapy of diseases that are caused by highly proliferative cells
10/17/2002	WO2002080913A1 Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
10/17/2002	WO2002080909A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
10/17/2002	WO2002080902A1 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
10/17/2002	WO2002080901A2 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates
10/17/2002	WO2002080890A2 A jasmonate pharmaceutical composition for treatment of cancer
10/17/2002	WO2002080889A2 A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080856A2 Triaza compound immunoregulatory agents
10/17/2002	WO2002080854A2 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	WO2002080851A2 Chimeric vaccines
10/17/2002	WO2002080849A2 Chemotherapeutic induction of egr-1 promoter activity
10/17/2002	WO2002080848A2 Methods and materials for cancer treatment
10/17/2002	WO2002080845A2 Novel eps8 compounds for therapy and diagnosis and methods for using same
10/17/2002	WO2002080844A2 Novel bgp compounds for therapy and diagnosis and methods for using same
10/17/2002	WO2002080676A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002	WO2002080648A2 Mucosal boosting following parenteral priming
10/17/2002	WO2002068414A3 Analogs of thalidomide as potential angiogenesis inhibitors
10/17/2002	WO2002057261A3 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
10/17/2002	WO2002054851A3 Inhibition of pathological angiogenesis in vivo
10/17/2002	WO2002050007A3 Substituted stilbenes, their reactions and anticancer activity
10/17/2002	WO2002044156A3 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
10/17/2002	WO2002043757A3 Medicament for preventing or treating tumors caused by human papilloma virus type 18
10/17/2002	WO2002043699A3 Preparation of large liposomes by infusion into peg
10/17/2002	WO2002043567A3 A method of treating cancer
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002	WO2002036733A9 Cd36 as a heat shock protein receptor and uses thereof
10/17/2002	WO2002036146A3 Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy
10/17/2002	WO2002036145A3 Kahalalide f formulation
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2002009645A3 Intercellular transport protein linked to an antigen as a molecular vaccine
10/17/2002	WO2001098354A3 Human receptors
10/17/2002	WO2001098344A3 Angiogenesis-modulating compositions and uses
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001083463A1 Oxadiazole derivatives having anticancer effects
10/17/2002	WO2001081551A3 Retinal pigment epithelial cell lines with extended life-span and their applications
10/17/2002	WO2001077378A3 Diagnosis of diseases associated with dna adducts
10/17/2002	WO2001074404A3 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
10/17/2002	WO2001060391A9 A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
10/17/2002	WO2001058922A9 Method and compositions for treating hepatocellular cancer
10/17/2002	WO2001054723A9 Therapeutic method for reducing angiogenesis
10/17/2002	WO2001049279A3 Use of steroidal alkaloids to reverse multidrug resistance
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	WO2001040497A3 Method for obtaining nucleic acids from an environment sample
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020151698 For diagnosis, prevention, and treatment of cancer, and neurological and immune disorders
10/17/2002	US20020151695 Transforming growth factor-beta-related molecules and uses thereof
10/17/2002	US20020151689 Method of killing target cells in harvested cell populations with one or more immuno-toxins
10/17/2002	US20020151680 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
10/17/2002	US20020151679 Peptide for use in the treatment of infections, viral and cancer diseases
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151575 Heterocyclic topoisomerase poisons
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors

1 ... 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 ... 2211